3Greipp P, Facon T, Williams CD, et al. A single subcutaneous dose of an osteoprotegerin ( OPG ) construct ( AMGN-0007 ) causes a profound and sustained decrease in bone resorption comparable to standard intravenous bisphosphonate in patients with multiple myeloma. Blood,2001,98 : 775a.
4Oyajobi BO, Franchin G', Williams PJ, et al. Dual effects of macrophage inflammatory protein-1 alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood, 2003,102 : 311-319.
5Zannettino AC, Farrugia AN, Kortesidis A, et al. Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res, 2005,65:1700-1709.
6Heider U, Fleissner C, Zavrski I, et al. Bone markers in multiple myeloma. Eur J Cancer,2006,42:1544-1553.
7Tian E, Zhan F, Walker R, et al. The role of the Wnt-signalling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med, 2003, 349 : 2483-2494.
8Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 2005,106:3160-3165.
9Oyajobi BO, Garrett IR, Gupta A, et al. Role of Dickkopf 1 (DKK) in myeloma bone disease and modulation by the proteasome inhibitor Velcade. 26th annual meeting of the American Society of Bone and Mineral Research. Seattle WA, 2004:1011.
10Mukherjee S, Raje N, Patel C, et al. Bortezomib induces proliferation of mesenchymal progenitor cells and promotes differentiation towards osteoblastic lineage. Blood,2006,108:88.
2Meda M, Adachi Y, Tomiyama J, et al. BonelesionsIn multiple myeloma differ between elderly and non-elderly patients [ J ]. Nippon Ronen Igakkai Zasshi,2002,39(6) :631-638.
3Terpos E, Dimopoulos MA. Myeloma bone disease : pathophysiology and management [ J ]. Ann Oncol, 2005,16 ( 8 ) : 1223-1231.
